The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: A comprehensive review

Human Psychopharmacology

Volumn 30, Issue 3, 2015, Pages 143-151

  Bellantuono, Cesario ^a   Vargas, Marianna ^a   Mandarelli, Gabriele ^b   Nardi, Bernardo ^a   Martini, Maria Giulia ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

breastfeeding; major malformations; perinatal complications; pregnancy; SNRI

Indexed keywords

DULOXETINE; MILNACIPRAN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VENLAFAXINE;

BREAST FEEDING; BREAST MILK; CONGENITAL MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HUMAN; INFANTILE SPASM; LACTATION; NECROTIZING ENTEROCOLITIS; NEWBORN DISEASE; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME; ABNORMALITIES, DRUG-INDUCED; NEWBORN; PREGNANCY COMPLICATIONS;

ABNORMALITIES, DRUG-INDUCED; BREAST FEEDING; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; INFANT, NEWBORN; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; VENLAFAXINE HYDROCHLORIDE;

EID: 84928105923     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2473     Document Type: Review

References (64)

1. Alder J, Fink N, Bitzer J, et al,. 2007. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 20: 189-209.
2. American College of Obstetricians and Gynecologists. 2008. Use of psychiatric drugs during pregnancy and lactation. ACOG Practice Bulletin 92. Obstet Gynecol 111: 1001-20.
3. Andrade C,. 2014. The safety of duloxetine during pregnancy and lactation. J Clin Psychiatry 75 (12): e1423-7.
4. Bakker MK, Kerstjens-Frederikse WS, Buys CH, et al,. 2010. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 88 (2): 94-100.
5. Balestrieri M, Isola M, Bisoffi G, et al,. 2012. Determinants of ante-partum depression: a multicenter study. Soc Psychiatry Psychiatr Epidemiol 47 (12): 1959-65.
6. Bellantuono C, Marini A, Lucarelli C,. 2013. Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. Clin Drug Investig 33 (9): 685-8.
7. Berle JØ, Steen VM, Aamo TO, et al,. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 65: 1228-34.
8. Borri C, Mauri M, Oppo A, et al,. 2008. Axis I psychopathology and functional impairment at the third month of pregnancy results from the Perinatal Depression Research and Screening Unit (PND-ReScU) Study. J Clin Psychiatry 69: 1617-1624.
9. Boucher N, Koren G, Beaulac-Baillargeon L,. 2009. Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Ther Drug Monit 31: 404-9.
10. Boyce PM, Hackett LP, Ilett KF,. 2011. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health 14: 169-72.
11. Briggs GG, Ambrose PJ, Ilett KF, et al,. 2009. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 43: 1898-902
12. Byers AL, Yaffe K, Covinsky KE, et al,. 2010. High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry 67: 489-96.
13. Calderon-Margalit R, Qiu C, Ornoy A, et al,. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 201: 579e1-8.
14. Cipriani A, Furukawa TA, Salanti G, et al,. 2009. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373: 746-58.
15. De Moor RA, Mourad L, ter Haar J, et al,. 2003. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 147: 1370-2.
16. Dubnov-Raz Juurlink DN, Fogelman R, et al,. 2008. Antenatal use of serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122 (3): e710-15.
17. Einarson A, Choi J, Einarson TR, et al,. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54: 242-6.
18. Einarson A, Fatoye B, Sarkar M, et al,. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 158 (10): 1728-30.
19. Einarson A, Koren G,. 2010. First trimester exposure to paroxetine and prevalence of defects: meta-analysis of the literature: unfortunately incomplete. Birth Defects Res A Clin Mol Teratol 88: 588.
20. Einarson A., Kelly Smart, Thiierry Vial, et al,. 2012. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry 73: 1471.
21. El Marroun H, Jaddoe VW, Hudziak JJ, et al,. 2012. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 69: 706-14.
22. Eyal R, Yaeger D,. 2008. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 165: 651.
23. Gentile S, Bellantuono C,. 2009. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine. J Clin Psychiatry 70: 414-22.
24. Gentile S., 2010. On categorizing gestational, birth, and neonatal complications following late pregnancy exposure to antidepressants: the prenatal antidepressant exposure syndrome. CNS Spectr 15: 167-85.
25. Grigoriadis S, VonderPorter EH, Mamisashvili L, et al,. 2013a. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 74 (4): e321-e341.
26. Grigoriadis S, VonderPorter EH, Mamisashvili L, et al,. 2013b. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry 74 (4): e309-e320.
27. Grote NK, Bridge JA, Gavin AR, et al,. 2010. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 67 (10): 1012-24.
28. Hale TW,. 2010. Medication and Mothers' Milk, 14th edn. Hale Publishing: Amarillo TX.
29. Hallberg P, Sjöblom V,. 2005. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 25: 59-73.
30. Hendrick V, Altshuler L, Wertheimer A, Dunn WA,. 2001. Venlafaxine and breast-feeding. Am J Psychiatry 158: 2089-90.
31. Hoog SL, Cheng Y, Elpers J, Dowsett SA,. Duloxetine and pregnancy outcomes: safety surveillance findings. 2013. Int J Med Sci 10: 413-9.
32. Hoppenbrouwers CJ, Bosma J, Wennink HJ, et al,. 2010. Neonatal seizures on EEG after in utero exposure to venlafaxine. Br J Clin Pharmacol 70: 454-6.
33. Huybrechts KF, Palmsten K, Avorn J, et al,. 2014a. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370 (25): 2397-407.
34. Huybrechts KF, Sanghani RS, Avorn J, et al,. 2014b. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One 9 (3): e92778.
35. Ilett KF, Hackett LP, Dusci LJ, et al,. 1998. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 45: 459-62.
36. Ilett KF, Kristensen JH, Hackett LP, et al,. 2002. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 53: 17-22.
37. Kallen B, Otterblad-Olausson PO, 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 17 (8): 801-6.
38. Kasper S, Pail G,. Milnacipran: a unique antidepressant? 2010. Neuropsychiatr Dis Treat 6: 23-31.
39. Kjaersgaard MI, Parner ET, Vestergaard M, et al,. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion-a population-based study. PLoS One 8 (8): e72095.
40. Koren G, Moretti M, Kapur B,. 2006. Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. J Obstet Gynaecol Can 28: 299-302.
41. Jimenez-Solem E, Andersen JT, Peterson M, et al,. 2013. Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort study. PLoS One 8 (4): e63034.
42. LactMed database. 2010. TOXNET. Available at: http://www.toxnet.nlm.nih.gov/index.html.
43. Lennestål R, Källén B,. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27: 607-13.
44. Lind JN, Tinker SC, Broussard CS, et al,. 2013. National Birth Defects Prevention Study. Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007. Pharmacoepidemiol Drug Saf 22 (7): 783-93.
45. Loughhead AM, Fisher AD, Newport DJ, et al,. 2006. Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 163: 145-7.
46. Malm H, Artama M, Gissler M, Ritvanen A,. 2011. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118 (1): 111-20.
47. Misri S, Corral M, Wardrop AA, Kendrick K,. 2006. Quetiapine augmentation in lactation: a series of case reports. J Clin Psychopharmacol 26: 508-11.
48. Nakhai-Pour HR, Broy P, Bérard A,. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182: 1031-7.
49. Newport DJ, Ritchie JC, Knight BT, et al,. 2009. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry 70: 1304-10.
50. NICE. 2007. Antenatal and postnatal mental health. Clinical management and service guidance. National Institute for Health and Care Excellence. www.nice.org.uk.
51. Orsolini L, Bellantuono C,. 2015. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacology 30 (1): 4-20.
52. Pakalapati RK, Bolisetty S, Austin MP, Oei J,. 2006. Neonatal seizures from in utero venlafaxine exposure. J Paediatr Child Health 42: 737-8.
53. Polen KN, Rasmussen SA, Riehle-Colarusso T, Reefhuis J,. 2013. National Birth Defects Prevention Study. Association between reported venlafaxine use in early pregnancy and birth defects, National Birth Defects Prevention Study, 1997-2007. Birth Defects Res A Clin Mol Teratol 97 (1): 28-35.
54. Pearlstein T., 2013. Use of psychotropic medication during pregnancy and the postpartum period. Womens Health (Lond Engl) 9 (6): 605-15.
55. Rampono J, Proud S, Hackett LP, et al,. 2004. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. Int J Neuropsychopharmacol 7: 329-34.
56. Rampono J, Simmer K, Ilett KF, et al,. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42: 95-100.
57. Ross LE, Grigoriadis S, Mamisashvili L, et al,. 2013. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 70 (4): 436-43.
58. Santone G, Ricchi G, Rocchetti D, et al,. 2009. Is the exposure to antidepressant drugs in early pregnancy a risk factor for spontaneous abortion? A review of available evidences. Epidemiol Psichiatr Soc 18 (3): 240-7.
59. Schueler YB, Koesters M, Wieseler B, et al,. 2011. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123 (4): 247-65.
60. Scottish Intercollegiate Guidelines Network (SIGN). Management of perinatal mood disorders. Edinburgh: SIGN; 2012. (SIGN publication no. 127). Available from URL: http://www.sign.ac.uk.
61. Treichel M, Schwendener Scholl K, Kessler U, et al,. 2009. Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? World J Pediatr 5 (1): 65-7.
62. Yaris F, Kadioglu M, Kesim M, et al,. 2004. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 19: 235-8.
63. Warburton W, Hertzman C, Oberlander TF,. 2010. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 121 (6): 471-9.
64. Wurst KE, Poole C, Ephross SA, Olshan AF,. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 88: 159-70.